Get the full picture
Sign in to uncover key details.
TriGemX Bio
Business Services · New York, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
430 E 29th St Ste 1050 Fl 10, New York, ...Website
www.trigemxbio.comRevenue
<$5 MillionIndustry
About TriGemX Bio
TriGemX Bio is a clinical-stage biotechnology company focused on developing innovative therapies for neurological diseases, particularly migraine. Based in New York City, the company leverages scientific discoveries in neural signaling pathways to develop novel treatments addressing significant unmet medical needs. Its lead drug candidate, elismetrep (K-304), is an investigational, oral, selective TRPM8 channel blocker being developed for the acute treatment of migraine. Currently in Phase 3 clinical trials, elismetrep represents a potential first-in-class therapeutic approach designed to provide effective relief for migraine patients. TriGemX Bio aims to advance innovative drug development, improve treatment outcomes.Explore more
TriGemX Bio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Frequently Asked Questions Regarding TriGemX Bio
Sign Up For FreeTo access detailed company insights
TriGemX Bio is a clinical-stage biotechnology company focused on developing innovative therapies for neurological diseases, particularly migraine. Based in New York City, the company leverages scientific discoveries in neural signaling pathways to develop novel treatments addressing significant unmet medical needs. Its lead drug candidate, elismetr... Read More
